Mesothelioma Olaparib Clinical Trial Targets Genetic Mutation

The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposure to asbestos, may be next. Several studies have shown that mutations of the BAP1 gene increase the risk of developing mesothelioma and favor the initial growth of the cancer cells. However, some scientists believe the mutation also makes the cancer cells more susceptible to therapy, making it a natural target for treatments such as olaparib. Clinical Trial Recruitment Underway Principal investigator Dr. Hedy Lee Kindler, director of the mesothelioma program and associate vice chair for clinical research at University of Chicago Medicine, is hoping to recruit 56 patients. She was not available to provide additional insight into the clinical trial. The study is designed primarily to measure the percentage of patients whose tumors shrink or stop growing in response to treatment. A secondary measurement will be overall survival and progression-f...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

More News: Asbestosis | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Genetics | Immunotherapy | Laboratory Medicine | Mesothelioma | Oral Cancer | Ovarian Cancer | Ovaries | Pain | Study